Study Evaluating 111In-Panitumumab for Nodal Staging in Head and Neck Cancer

Inclusion Criteria:

   - Biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck.

   - Subjects diagnosed with any T stage, any subsite within the head and neck that are
   scheduled to undergo surgical resection. Subjects with recurrent disease or a new
   primary will be allowed.

   - Planned standard of care elective neck dissection for a cN0 or cN1 disease. Clinical
   N1 disease will be defined as metastasis in a single, ipsilateral lymph node, 3 cm or
   less in greatest dimension by clinical exam, cross sectional imaging or metabolic
   imaging.

   - Have acceptable hematologic status, coagulation status, kidney function, and liver
   function including the following clinical results:

   - Hemoglobin ≥ 9 gm/dL

   - White blood cell count > 3000/mm3

   - Platelet count ≥ 100,000/mm3

   - Serum creatinine ≤ 1.5 times upper reference range

Exclusion Criteria:

   - Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive
   heart failure (CHF); significant liver disease; or unstable angina within 6 months
   prior to enrollment.

   - History of infusion reactions to monoclonal antibody therapies.

   - Pregnant or breastfeeding.

   - Magnesium or potassium lower than the normal institutional values.

   - Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide,
   amiodarone, sotalol) antiarrhythmic agents.

   - Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis.

   - Severe renal disease or anuria.